The "off-label" uses of approved drugs have been an important tool for advancing the treatment of cancer. ASCO's position states that third-party payers should be required to cover off-label indications for anti-cancer drugs if such indications are listed in the compendia or supported in peer-reviewed medical literature. Below you can find ASCO’s position on the coverage of unlabeled drug indications.
